In addition, it was shown that compared to nivolumab combination chemotherapy, Opdualag combination chemotherapy improved ORR (53.2% vs. 40.8%), prolonged mPFS (9.8 vs. 6.1 months), and had an HR of 0.63 in this group of NSCLC patients with PDL1 ≥ 1%; and, for non-squamous NSCLC (non-sq-NSCLC) patients with PD-L1 TPS≥1%, the ORR improved to 58%, the mPFS increased to 11.6 months, and the HR was further reduced to 0.55 (140). The gene discussed is CD274; the disease is non-small cell lung carcinoma.